Programmable specificity.
Guide RNA sequences direct the editing system toward conserved viral elements while preserving healthy host DNA.
Viruses evolve. Patients adapt. Our science is focused on the hidden biology that keeps chronic infection in place.
Current antiviral therapies can be life-changing, but for many infections they require daily or periodic treatment for life. When therapy stops, the viral reservoir can reactivate.
That is the biological space we are designed to reach: the integrated or episomal viral DNA that conventional medicines cannot remove.
Our approach pairs programmable nucleases with delivery and molecular design strategies engineered for viral targets.
Guide RNA sequences direct the editing system toward conserved viral elements while preserving healthy host DNA.
Precisely designed cuts are intended to disrupt or remove viral genetic material that enables persistence.
We build for the realities of patients: delivery, tolerability, repeatability and a clear path to the clinic.
Our research lens
Every experiment starts with the same question: can this meaningfully change the lives of people who have spent years managing their disease?
We interrogate target biology, off-target risk and delivery constraints together—not as disconnected steps.
Our translational decisions are anchored in reproducible data and a disciplined understanding of what it takes to move forward.
The best endpoint is not just a molecular one. It is a patient who can plan a future beyond chronic management.
Explore the programs taking our platform from concept to the next stage of development.
Explore programs ↗